{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"207.686","value":"1410.000"},{"groupId":"OG001","spread":"1460.411","value":"3280.000"}]}],"title":"Cmin,ss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"475.000","value":"2177.50"},{"groupId":"OG001","spread":"1515.333","value":"4213.33"}]}],"title":"Cmax,ss"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points. Pharmacokinetic analysis of major metabolite of Niraparib (M1) was conducted using standard non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 1: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 1: Niraparib 300 mg + Pembrolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1(each cycle of 21 days)","title":"Phase 1: Cmin,ss and Cmax,ss of Major Metabolite of Niraparib (M1)","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}